Key facts
- Aspivix’s last known valuation is $28.4M.
- It has raised $20.1M; the latest was Equity Crowdfunding ($2.8M) in Mar 2025.
- Notable investors include MassChallenge, Venture Kick, Innosuisse, Zürcher Kantonalbank, 4FOX Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Aspivix
- ·The full record, as it builds
Funding rounds
No funding rounds for Aspivix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aspivix
Developer of a suction cervical stabilizer designed to reduce pain and eliminate the risk of lesions and bleeding in women for gynecological purposes. The company's device is based on a patented suction pad technology that facilitates the gentle handling of cervix pain during gynecological procedures, enabling physicians to avoid normal bleeding, cervical tears, and lacerations, protecting patients from the risk of developing cross-infections.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2015
- Employees
- 9
- Website
- aspivix.com/
- Ownership
- Privately Held (backing)
Aspivix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aspivix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aspivix in its N-PORT filings yet. We sweep new filings monthly.